Q-omics provides the consensus-scored CEP290 profile across patient tissues and cancer cell-line models. CEP290 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CEP290 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CEP290 RNA expression shows 21,869 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where CEP290 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP290 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP290 survival associations across molecular data types. CEP290 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP290 RNA expression–survival associations across cancer types. High CEP290 expression shows unfavorable associations in KIRC, LIHC, HNSC and LGG, but favorable associations in UCS and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CEP290 RNA expression.
This table summarizes CEP290 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CEP290. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP290 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, KIRP, LIHC and BLCA. The HNSC box plot shows higher CEP290 RNA expression in tumor versus normal tissue (log2 FC = +1.087, t-test p < 0.001).
This table shows molecular features associated with CEP290 in patient tissues and cancer cell lines. In patient samples, CEP290 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP290 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
